Nuformix PLC (LON:NFX) said its NXP004 fibrosis programme in human idiopathic pulmonary fibrosis (IPF) had showed promise in a key area in early-stage pre-clinical trials. 

IPF is characterised by excessive deposition and remodelling of extracellular matrix (ECM), said the AIM-listed company, leading to lung scarring and loss of respiratory function.

Over-production of ECM components are a driver in IPF progression and NXP004 showed a dose-dependent reduction in the secretion of these key components, Nuformix said.

The data also suggests NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model.

Results of the study were delayed by staff at the company’s Newcastle Fibrosis Research Group (NFRG) helping the government in its efforts against COVID-19, Nuformix said, adding the delivery of a full pre-clinical study data set is the next focus.

Joanne Holland, Nuformix’s chief scientific officer, said: ” Whilst this is only the pilot phase of this pre-clinical study, positive indications of anti-fibrotic activity are very encouraging.

“We would like to thank our research partner NFRG for prioritising completion of this study under challenging circumstances.”